prediction

On balance of probability, this is how I see things playing out ...

A major global pharma will take a 15% position in PYC and simultaneously announce a series of drug development programmes.

The premium payable for the 15% will shock a lot of people.

Over the next 6 months, a number of other drug development programmes will be announced.

Any current antibody or affibody development can be better targetted with a Phylomer. This is because screening is easier, stability of the drug is higher, affinity is equal or better, license/royalty costs are cheaper.

My great fear is that we get taken out, at this stage. If we own this company during it's next stage of development ... we will end up own a multi-billion$, global, section of the world's pharmaceutical market.

We should be spinning off the golden eggs ... not selling the golden goose.

BTW the market is completely unaware of the potential of this company ... it will be a 6 month bull run up as news finally gets to market and people finally wake up and smell the coffee.

Ladies and Gentlemen, if you are long on PYC ... you should be very happy. If you are not ... go out and research a stake in BTC.ASX.